Barclays increases target price of Integra Lifesciences stock to $70 — 4 quick facts

Integra Lifesciences stock had its price target increased by Barclays from $63 to $70 in a research report sent on May 29, according to a Dakota Financial News report.

Advertisement

Here are four quick facts:

 

1. Integra Lifesciences has a 52-week low of $44.11 and a 52-week high of $69.03.

 

2. The stock’s 50-day moving average is $63 and its 200-day moving average is $57.

 

3. The company has a market cap of $2.23 billion.

 

4. On average, the company has a rating of ‘buy’ and an average price target of $69.

 

More articles on devices:
MIS SI joint fusions: 5 key notes on the NASS coverage recommendation
Materialise partners with Consensus Orthopedics — 4 things to know
Mazor Robotics gets “buy” rating — 6 quick updates

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.